WO1998042344A1 - Pharmaceutical composition - Google Patents
Pharmaceutical composition Download PDFInfo
- Publication number
- WO1998042344A1 WO1998042344A1 PCT/GB1998/000885 GB9800885W WO9842344A1 WO 1998042344 A1 WO1998042344 A1 WO 1998042344A1 GB 9800885 W GB9800885 W GB 9800885W WO 9842344 A1 WO9842344 A1 WO 9842344A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- active ingredient
- buspirone
- medicament
- manufacture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98912622A EP0969842A1 (en) | 1997-03-24 | 1998-03-24 | Pharmaceutical composition |
JP54523598A JP2001518925A (en) | 1997-03-24 | 1998-03-24 | Pharmaceutical composition |
AU67402/98A AU6740298A (en) | 1997-03-24 | 1998-03-24 | Pharmaceutical composition |
US10/375,560 US20040023948A1 (en) | 1997-03-24 | 2003-02-26 | Fast-dispersing dosage form containing 5-HT1 agonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9706089.1A GB9706089D0 (en) | 1997-03-24 | 1997-03-24 | Pharmaceutical composition |
GB9706089.1 | 1997-03-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US40859599A Continuation | 1997-03-24 | 1999-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998042344A1 true WO1998042344A1 (en) | 1998-10-01 |
Family
ID=10809779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/000885 WO1998042344A1 (en) | 1997-03-24 | 1998-03-24 | Pharmaceutical composition |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0969842A1 (en) |
JP (1) | JP2001518925A (en) |
AU (1) | AU6740298A (en) |
GB (1) | GB9706089D0 (en) |
WO (1) | WO1998042344A1 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1164994A1 (en) * | 1999-03-03 | 2002-01-02 | R.P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
EP1256343A1 (en) * | 2001-05-11 | 2002-11-13 | Jürgen K. Dr. Beck | Flibanserin for the treatment of extrapyramidal movement disorders |
EP1266656A1 (en) * | 2000-03-01 | 2002-12-18 | American Pharmaceutical International | Anionic exchange polymer complexes of buspirone |
WO2003013539A1 (en) * | 2001-08-10 | 2003-02-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neuroprotective drug |
WO2003047552A2 (en) * | 2001-12-05 | 2003-06-12 | Glaxo Group Limited | Pharmaceutical composition comprising a 5ht1 receptor agonist |
WO2004002487A1 (en) * | 2002-06-28 | 2004-01-08 | Fabre-Kramer Pharmaceuticals, Inc. | Methods for treating attention deficit disorder |
EP1408976A1 (en) * | 2001-07-20 | 2004-04-21 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
WO2004069339A1 (en) * | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
WO2005092338A1 (en) * | 2004-03-25 | 2005-10-06 | Solvay Pharmaceuticals B.V. | Process for the preparation of 3-amino-8-(1-piperazinyl) -2h-1-benzopyran-2-one and salts and hydrates thereof |
WO2006005760A1 (en) * | 2004-07-15 | 2006-01-19 | Solvay Pharmaceuticals B.V. | Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one |
WO2006024471A1 (en) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
WO2006119958A2 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of chronic pain |
US7151103B2 (en) | 2001-10-20 | 2006-12-19 | Boehringer Ingelheim Pharma Kg | Method of treating female hypoactive sexual desire disorder with flibanserin |
US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
WO2007093624A2 (en) * | 2006-02-18 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
WO2007096300A1 (en) * | 2006-02-20 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of urinary incontinence |
US7923449B2 (en) | 2005-10-29 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US8106074B2 (en) | 2001-07-13 | 2012-01-31 | Pierre Fabre Medicament | Pyridin-2-yl-methylamine derivatives for treating opiate dependence |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
CN1915233B (en) * | 2006-08-30 | 2012-10-03 | 四川科瑞德制药有限公司 | Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation |
US8512748B2 (en) | 2006-08-25 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
US8658207B2 (en) | 2006-08-14 | 2014-02-25 | Boehringer Ingelheim International Gmbh | Extended release tablet formulations of flibanserin and method for manufacturing the same |
US9226904B2 (en) | 2006-02-28 | 2016-01-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
US20160058762A1 (en) * | 2010-10-15 | 2016-03-03 | Contera Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
US9763936B2 (en) | 2006-06-30 | 2017-09-19 | Sprout Pharmaceuticals, Inc. | Flibanserin for the treatment of urinary incontinence and related diseases |
US10166230B2 (en) | 2007-09-12 | 2019-01-01 | Sprout Pharmaceuticals Inc. | Treatment of vasomotor symptoms |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
CN113880815A (en) * | 2020-07-03 | 2022-01-04 | 中国药科大学 | Indole derivatives and preparation method and application thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007510629A (en) * | 2003-10-22 | 2007-04-26 | イーライ リリー アンド カンパニー | Novel MCH receptor antagonist |
JP2009536667A (en) * | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | 5HT receptor-mediated neurogenesis |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
EP0220696A2 (en) * | 1985-10-25 | 1987-05-06 | Bristol-Myers Squibb Company | Use of buspirone for preparing pharmaceutical compositions for alleviation of phobic anxiety |
EP0276536A2 (en) * | 1986-10-07 | 1988-08-03 | Bristol-Myers Squibb Company | Use of buspirone for the improvement of short term memory |
JPS63250318A (en) * | 1987-04-06 | 1988-10-18 | Fujimoto Seiyaku Kk | Pharmaceutical preparation suitable in oral cavity |
EP0313535A1 (en) * | 1987-10-22 | 1989-04-26 | Bristol-Myers Squibb Company | Oral formulation of buspirone and salts thereof |
EP0354777A2 (en) * | 1988-08-10 | 1990-02-14 | Glaxo Group Limited | 3-(4-Piperidine)-5-(2-sulfonylaminoethyl) indole derivatives |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
JPH04360826A (en) * | 1991-06-07 | 1992-12-14 | Bayer Yakuhin Kk | Controlled release pharmaceutical preparation |
EP0546593A1 (en) * | 1991-10-30 | 1993-06-16 | Glaxo Group Limited | Multi-layered compositions containing histamine or serotonin antagonists |
US5246710A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating cyclothymia |
US5246711A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating dysthymia |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
WO1994014772A1 (en) * | 1992-12-21 | 1994-07-07 | Smithkline Beecham Plc | Enantiomers of carbazole derivatives as 5-ht1-like agonists |
WO1994025023A1 (en) * | 1993-04-27 | 1994-11-10 | Pfizer Inc. | Use of indole derivatives as 5ht1 antagonists |
EP0629402A1 (en) * | 1993-06-15 | 1994-12-21 | Bayer Ag | Pharmaceutical compositions containing ipsapirone |
US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
WO1996006842A1 (en) * | 1994-08-27 | 1996-03-07 | Pfizer Limited | Salts of an anti-migraine indole derivative |
EP0705600A1 (en) * | 1994-10-05 | 1996-04-10 | Eli Lilly And Company | Use of 5-HT1F-receptor agonists for the treatment of migraine |
EP0749962A1 (en) * | 1995-06-23 | 1996-12-27 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles |
WO1998002186A1 (en) * | 1996-07-11 | 1998-01-22 | Farmarc Nederland B.V. | Inclusion complex containing indole selective serotonin agonist |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI9111010B (en) * | 1990-06-07 | 2005-02-28 | Astrazeneca Ab | 3,5-disubstituted indole derivatives as "5-ht1-similar" receptor agonists |
-
1997
- 1997-03-24 GB GBGB9706089.1A patent/GB9706089D0/en active Pending
-
1998
- 1998-03-24 AU AU67402/98A patent/AU6740298A/en not_active Abandoned
- 1998-03-24 WO PCT/GB1998/000885 patent/WO1998042344A1/en active Application Filing
- 1998-03-24 EP EP98912622A patent/EP0969842A1/en not_active Withdrawn
- 1998-03-24 JP JP54523598A patent/JP2001518925A/en not_active Ceased
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
EP0220696A2 (en) * | 1985-10-25 | 1987-05-06 | Bristol-Myers Squibb Company | Use of buspirone for preparing pharmaceutical compositions for alleviation of phobic anxiety |
EP0276536A2 (en) * | 1986-10-07 | 1988-08-03 | Bristol-Myers Squibb Company | Use of buspirone for the improvement of short term memory |
JPS63250318A (en) * | 1987-04-06 | 1988-10-18 | Fujimoto Seiyaku Kk | Pharmaceutical preparation suitable in oral cavity |
EP0313535A1 (en) * | 1987-10-22 | 1989-04-26 | Bristol-Myers Squibb Company | Oral formulation of buspirone and salts thereof |
EP0354777A2 (en) * | 1988-08-10 | 1990-02-14 | Glaxo Group Limited | 3-(4-Piperidine)-5-(2-sulfonylaminoethyl) indole derivatives |
US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
JPH04360826A (en) * | 1991-06-07 | 1992-12-14 | Bayer Yakuhin Kk | Controlled release pharmaceutical preparation |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
EP0546593A1 (en) * | 1991-10-30 | 1993-06-16 | Glaxo Group Limited | Multi-layered compositions containing histamine or serotonin antagonists |
US5246711A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating dysthymia |
US5246710A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating cyclothymia |
WO1994014772A1 (en) * | 1992-12-21 | 1994-07-07 | Smithkline Beecham Plc | Enantiomers of carbazole derivatives as 5-ht1-like agonists |
WO1994025023A1 (en) * | 1993-04-27 | 1994-11-10 | Pfizer Inc. | Use of indole derivatives as 5ht1 antagonists |
EP0629402A1 (en) * | 1993-06-15 | 1994-12-21 | Bayer Ag | Pharmaceutical compositions containing ipsapirone |
WO1996006842A1 (en) * | 1994-08-27 | 1996-03-07 | Pfizer Limited | Salts of an anti-migraine indole derivative |
US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
EP0705600A1 (en) * | 1994-10-05 | 1996-04-10 | Eli Lilly And Company | Use of 5-HT1F-receptor agonists for the treatment of migraine |
EP0749962A1 (en) * | 1995-06-23 | 1996-12-27 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles |
WO1998002186A1 (en) * | 1996-07-11 | 1998-01-22 | Farmarc Nederland B.V. | Inclusion complex containing indole selective serotonin agonist |
Non-Patent Citations (6)
Title |
---|
DATABASE WPI Week 9304, Derwent World Patents Index; AN 93-032652, XP002040477 * |
PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 * |
ROUGE: "Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery", INT. J. PHARMACEUTICS, vol. 136, no. 1-2, 1996, pages 117 - 139, XP002040474 * |
See also references of EP0969842A1 * |
TAY: "The site of gastrointestinal absorption of gepirone in humans", J. CLIN. PHARMACOL., vol. 32, September 1992 (1992-09-01), pages 827 - 832, XP002040475 * |
YU: "Oral cavity absorption of (R)-8-hydroxy-2-(di-n-propylamino)tetralin and (s)-8-acetyl-2-(di-n-propylamino)tetralin in the rat", J. PHARM. PHARMACOL., vol. 48, no. 1, January 1996 (1996-01-01), pages 41 - 45, XP002040476 * |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1164994A1 (en) * | 1999-03-03 | 2002-01-02 | R.P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
EP1164994A4 (en) * | 1999-03-03 | 2004-05-26 | Scherer Technologies Inc R P | Opioid agonist in a fast dispersing dosage form |
EP1266656A1 (en) * | 2000-03-01 | 2002-12-18 | American Pharmaceutical International | Anionic exchange polymer complexes of buspirone |
US8030314B2 (en) | 2001-05-11 | 2011-10-04 | Beck Juergen K | Use of 2h-benzimidazol-2-one, 1,3-dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable acid addition salts |
WO2002092088A3 (en) * | 2001-05-11 | 2003-01-30 | Juergen K Beck | Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts |
JP4634008B2 (en) * | 2001-05-11 | 2011-02-16 | カー. ベック ユルゲン | 2H-benzimidazol-2-one, 1,3-dihydro-1- (2- {4- [3- (trifluoromethyl) phenyl] -1-piperazinyl} ethyl)-and its physiologically acceptable acids New use of addition salts |
AU2002310813B2 (en) * | 2001-05-11 | 2008-04-03 | Jurgen K. Beck | Flibanserin for the treatment of extrapyramidal movement disorders |
WO2002092088A2 (en) * | 2001-05-11 | 2002-11-21 | Beck Juergen K | Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts |
EP1256343A1 (en) * | 2001-05-11 | 2002-11-13 | Jürgen K. Dr. Beck | Flibanserin for the treatment of extrapyramidal movement disorders |
JP2004529175A (en) * | 2001-05-11 | 2004-09-24 | カー. ベック ユルゲン | 2H-benzimidazol-2-one, 1,3-dihydro-1- (2- {4- [3- (trifluoromethyl) phenyl] -1-piperazinyl} ethyl)-and its physiologically acceptable acids New use of addition salt |
US8106074B2 (en) | 2001-07-13 | 2012-01-31 | Pierre Fabre Medicament | Pyridin-2-yl-methylamine derivatives for treating opiate dependence |
EP1408976A4 (en) * | 2001-07-20 | 2007-05-16 | Psychogenics Inc | Treatment for attention-deficit hyperactivity disorder |
EP1408976A1 (en) * | 2001-07-20 | 2004-04-21 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US7420057B2 (en) | 2001-08-02 | 2008-09-02 | Boehringer Ingelheim Pharma Kg | Stable polymorph of flibanserin |
EP1767209A1 (en) * | 2001-08-10 | 2007-03-28 | Boehringer Ingelheim Pharma GmbH & Co. KG | Neuroprotective drug |
WO2003013539A1 (en) * | 2001-08-10 | 2003-02-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neuroprotective drug |
US7151103B2 (en) | 2001-10-20 | 2006-12-19 | Boehringer Ingelheim Pharma Kg | Method of treating female hypoactive sexual desire disorder with flibanserin |
US9782403B2 (en) | 2001-10-20 | 2017-10-10 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US11058683B2 (en) | 2001-10-20 | 2021-07-13 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
WO2003047552A2 (en) * | 2001-12-05 | 2003-06-12 | Glaxo Group Limited | Pharmaceutical composition comprising a 5ht1 receptor agonist |
WO2003047552A3 (en) * | 2001-12-05 | 2003-09-25 | Glaxo Group Ltd | Pharmaceutical composition comprising a 5ht1 receptor agonist |
EP1527773A1 (en) * | 2001-12-05 | 2005-05-04 | Glaxo Group Limited | Pharmaceutical composition comprising sumatriptan |
WO2004002487A1 (en) * | 2002-06-28 | 2004-01-08 | Fabre-Kramer Pharmaceuticals, Inc. | Methods for treating attention deficit disorder |
WO2004069339A1 (en) * | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
US7776860B2 (en) | 2004-03-25 | 2010-08-17 | Solvay Pharmaceuticals B.V. | Process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one and salts and solvates thereof |
WO2005092338A1 (en) * | 2004-03-25 | 2005-10-06 | Solvay Pharmaceuticals B.V. | Process for the preparation of 3-amino-8-(1-piperazinyl) -2h-1-benzopyran-2-one and salts and hydrates thereof |
US8173660B2 (en) | 2004-03-25 | 2012-05-08 | Solvay Pharmaceuticals B.V. | Process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one and salts and solvates thereof |
WO2006005760A1 (en) * | 2004-07-15 | 2006-01-19 | Solvay Pharmaceuticals B.V. | Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one |
WO2006024471A1 (en) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
WO2006119884A3 (en) * | 2005-05-06 | 2007-03-22 | Boehringer Ingelheim Int | Method for the treatment of drug abuse with flibanserin |
WO2006119958A2 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of chronic pain |
WO2006119958A3 (en) * | 2005-05-13 | 2007-03-22 | Boehringer Ingelheim Int | Use of flibanserin in the treatment of chronic pain |
US10874668B2 (en) | 2005-08-03 | 2020-12-29 | Sprout Pharmaceuticals, Inc. | Use of Flibanserin in the treatment of obesity |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US10335407B2 (en) | 2005-08-03 | 2019-07-02 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US9730927B2 (en) | 2005-08-03 | 2017-08-15 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US7923449B2 (en) | 2005-10-29 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
WO2007093624A3 (en) * | 2006-02-18 | 2007-11-15 | Boehringer Ingelheim Int | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
WO2007093624A2 (en) * | 2006-02-18 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
WO2007096300A1 (en) * | 2006-02-20 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of urinary incontinence |
US9226904B2 (en) | 2006-02-28 | 2016-01-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
US9763936B2 (en) | 2006-06-30 | 2017-09-19 | Sprout Pharmaceuticals, Inc. | Flibanserin for the treatment of urinary incontinence and related diseases |
US10004731B2 (en) | 2006-06-30 | 2018-06-26 | Sprout Pharmaceuticals, Inc. | Flibanserin for the treatment of urinary incontinence and related diseases |
US8658207B2 (en) | 2006-08-14 | 2014-02-25 | Boehringer Ingelheim International Gmbh | Extended release tablet formulations of flibanserin and method for manufacturing the same |
US8512748B2 (en) | 2006-08-25 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
CN1915233B (en) * | 2006-08-30 | 2012-10-03 | 四川科瑞德制药有限公司 | Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation |
US10166230B2 (en) | 2007-09-12 | 2019-01-01 | Sprout Pharmaceuticals Inc. | Treatment of vasomotor symptoms |
US10632116B2 (en) * | 2010-10-15 | 2020-04-28 | Contera Pharma A/S | Combinations of serotonin receptor agonists for treatment of movement disorders |
US20160058762A1 (en) * | 2010-10-15 | 2016-03-03 | Contera Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
CN113880815A (en) * | 2020-07-03 | 2022-01-04 | 中国药科大学 | Indole derivatives and preparation method and application thereof |
CN113880815B (en) * | 2020-07-03 | 2024-03-29 | 中国药科大学 | Indole derivatives, preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AU6740298A (en) | 1998-10-20 |
GB9706089D0 (en) | 1997-05-14 |
EP0969842A1 (en) | 2000-01-12 |
JP2001518925A (en) | 2001-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040023948A1 (en) | Fast-dispersing dosage form containing 5-HT1 agonists | |
EP0969842A1 (en) | Pharmaceutical composition | |
US6946141B2 (en) | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | |
JP5179757B2 (en) | Composition for delivering a hypnotic agent through the oral mucosa and method of use thereof | |
AU717337B2 (en) | Dosage forms and method for ameliorating male erectile dysfunction | |
WO2000020033A1 (en) | Tablets immediately disintegrating in the oral cavity | |
BR112020011238A2 (en) | FORMULATION OF SOLID ORAL NICOTIN TO RELIEVE DESIRE OF NICOTINE QUICK START, FORMULATION OF SOLID ORAL NICOTINE FOR USE IN ATTENUING NICOTIN DESIRE, METHOD OF ATTENUATING NICOTIN DESIRE AND ORAL PURSE | |
AU702161B2 (en) | Pharmaceutical compositions comprising monoamine oxidase B inhibitors | |
JPWO2005037254A1 (en) | Tablet Quickly Disintegrating in Oral Cavity | |
PT833619E (en) | CONTROLLED DRUG LIBERALIZATION BY SUBLINGUAL OR ORAL ADMINISTRATION | |
EP1961413A1 (en) | Rapidly disintegratable oral tablet | |
US20030022910A1 (en) | Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine | |
JP6507272B2 (en) | Tofacitinib orally disintegrating tablet | |
CA3200444A1 (en) | Solid pharmaceutical compositions and methods of producing the same | |
CA2556450C (en) | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof | |
JP2003261439A (en) | Preparation disintegrating in oral cavity | |
US9675551B2 (en) | Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof | |
US10111832B2 (en) | Orodispersible tablets obtained by compression molding | |
JP2665357B2 (en) | Pharmaceutical composition for treating heart failure | |
WO2021171318A1 (en) | Transmucosal pharmaceutical composition of levocetirizine | |
US20030198669A1 (en) | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine | |
Gujarati | Oral Disintegrating Tablets: Background and Review on Recent Advancements | |
EP4311543A1 (en) | Methods for loading template inverted carriers | |
EP2566452A1 (en) | Melting tablet comprising a triptane or atypical neuroleptic | |
TW200423929A (en) | Pharmaceutical combination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998912622 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09408595 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 545235 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998912622 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |